Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
NEW YORK–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of two preclinical drug candidates which target obesity and neuroblastoma, respectively. About CLS-1: Treatment of obesity via modulation of chemical signaling relating to gut microbiota Under the … Skaityti toliau